Warner Bros. Discovery will be reorganized into two major departments. Warner Bros. Discovery said that it will be reorganized into two operating departments, one focusing on traditional cable TV business and the other focusing on streaming media and studios, which may pave the way for the company's future transactions. Warner Bros. Exploration said that it will merge its current Max and Discovery+ streaming media services and HBO departments with another department including Warner Bros.' film and television production business.Asiana Airlines will use Korean Air's 1.500 trillion won investment to repay its debts.Meta released a new AI tool, which can enhance the experience of the Meta-universe. On Thursday, the American technology giant Meta said that it would release an artificial intelligence model called Meta Motivo, which can control the actions of a digital agent similar to human beings and may enhance the experience of the meta-universe. According to the company, Meta Motivo solves the common body control problems in digital avatars, enabling them to exercise in a more realistic and human-like way. "We believe that this research can pave the way for a fully concrete agent in the meta-universe, resulting in a more realistic NPC (non-player character), democratization of character animation, and a new immersive experience."
The American medical insurance giant said that the suspect who assassinated its CEO was not a company customer. A spokesman for UnitedHealth Group said that Luigi Mangione, the suspect accused of killing Brian Thompson, CEO of the company's United Health Care, was not a member of the company's insurance plan. Unitedhealth group said that Man Ghione and his mother were not members of United Health Insurance Company, and refuted the claim that the shooting incident was caused by dissatisfaction caused by his special experience in the company.Onlikon: The cooperative product Aidit calcitonin soft capsules is planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13th, and on December 12th, the company received a notice from its partner Beijing Meifurun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Meifurun") that the Aidit calcitonin soft capsules jointly developed by the company and its wholly-owned subsidiary Wenzhou Haihe Pharmaceutical Co., Ltd. are planned to be selected for the tenth batch of national centralized drug procurement. According to the Pharmaceutical Cooperation Agreement signed by the company and its partner Mei Furun, the company owns 50% of the cooperative products.According to people familiar with the matter, Trump's advisers and officials from his newly formed government efficiency department asked him if he could abolish the Federal Deposit Insurance Corporation (FDIC).
Cathay Pacific: The number of the group has exceeded 30,000, and there will be more than 100 passenger destinations next year. On December 13, Cathay Pacific said that it had the largest recruitment in history in 2024, with about 7,000 new employees hired throughout the year, and the total number of employees in the group exceeded 30,000. With the total flight volume of Cathay Pacific and Hong Kong Express returning to the pre-epidemic level in January next year, Cathay Pacific announced that the two-year reconstruction trip will be completed soon, and there will be more than 100 passenger destinations next year. (Hong Kong Economic Times)Ministry of Finance of Korea: If the volatility is excessively intensified, more market stabilization measures will be taken.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.